Your Messages Inbox
Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. 2008 Exclusive Survey—Earnings: Good news for primary care income 3. Medicare pay-for-reporting effort draws fire from frustrated doctors 4. Debunking Myths in the US Healthcare System 5. EGFR inhibitors as first-line therapy in advanced non-small cell lung cancer
Your Article Summary
See Latest ArticlesBreast cancer resistant protein (BCRP) is a molecular determinant of the outcome of photodynamic therapy (PDT) for centrally located early lung cancer
Lung Cancer, 07/02/09
Usuda J et al. - Photofrin may be a substrate of BCRP and be pumped out from the cells, therefore, BCRP may be a molecular determinant of the outcome of Photofrin-PDT.
Related Articles
Lung cancer: a biologically different disease in women?
Women's Health, 10/30/09
Relevance Score: 73%
Oestrogen plus progestin and lung cancer in postmenopausal women (Womens Health Initiative trial): a post-hoc analysis of a randomised controlled trial
The Lancet, 10/12/09
Relevance Score: 72%
Haplotype and Cell Proliferation Analyses of Candidate Lung Cancer Susceptibility Genes on Chromosome 15q24-25.1
Cancer Research, 10/06/09
Relevance Score: 71%
Noninvasive detection of lung cancer by analysis of exhaled breath
BMC Cancer, 10/09/09
Relevance Score: 70%
African American lung cancer patients may have different response to new cancer-fighting drugs
EurekAlert, 10/08/09
Relevance Score: 70%
Today in Lung/Thoracic Oncology...keeping you current
Receive free subspecialty "5-minute updates" via email
18FDG-PET-CT in the follow-up of non-small cell lung cancer patients after radical radiotherapy with or without chemotherapy: An economic evaluation
European Journal of Cancer, 12/10/09
Tissue diagnosis of new lung nodules in patients with a known malignancy
The American Journal of Surgery, 12/10/09
Stage I nonsmall cell lung cancer in patients aged >=75 years
Cancer, 12/10/09
Sponsor
Article Search
Sponsor
Sponsor